Research location
Mayfield
Ohio, United States
Advertisement
Research activity in Mayfield
Ohio, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 19 trials and 19 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Mayfield
19 linked trials · page 1 of 1A Study of LY2127399 in Rheumatoid ArthritisNCT01576549 · 2012-05-01 · 1 site observation
TERMINATED
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid ArthritisNCT01285310 · 2010-12-09 · 1 site observation
TERMINATED
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid ArthritisNCT01261403 · 2010-12-01 · 1 site observation
TERMINATED
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)NCT01004432 · 2009-12-01 · 1 site observation
COMPLETED
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)NCT00891020 · 2009-05-01 · 1 site observation
COMPLETED
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate TreatmentNCT00810199 · 2009-03-01 · 1 site observation
COMPLETED
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid ArthritisNCT00717236 · 2008-07-01 · 1 site observation
COMPLETED
RESTART C0168Z05 Rheumatoid Arthritis StudyNCT00714493 · 2008-07-01 · 1 site observation
COMPLETED
A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid ArthritisNCT00531817 · 2007-10-01 · 1 site observation
COMPLETED
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)NCT00476996 · 2007-05-15 · 1 site observation
TERMINATED
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid ArthritisNCT00413699 · 2007-02-05 · 1 site observation
COMPLETED
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenNCT00346216 · 2006-10-04 · 1 site observation
COMPLETED
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)NCT00299546 · 2006-02-01 · 1 site observation
COMPLETED
A Safety and Pharmacokinetics Study in Participants With Rheumatoid ArthritisNCT00380744 · 2005-11-01 · 1 site observation
COMPLETED
A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid ArthritisNCT00109408 · 2005-07-01 · 1 site observation
COMPLETED
A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa TherapiesNCT02097745 · 2004-06-01 · 1 site observation
COMPLETED
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha TherapyNCT00468546 · 2003-05-01 · 1 site observation
COMPLETED
Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)NCT02093026 · 2002-08-01 · 1 site observation
COMPLETED
ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid ArthritisNCT00048321 · 2002-01-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.